Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis

Gut Pathogens

Volumn 6, Issue 1, 2014, Pages

  Luerce, Tessalia Diniz ^a   Gomes Santos, Ana Cristina ^a   Rocha, Clarissa Santos ^a   Moreira, Thais Garcias ^b   Cruz, Déborah Nogueira ^a   Lemos, Luísa ^a   Sousa, Adna Luciana ^a   Pereira, Vanessa Bastos ^a   De Azevedo, Marcela ^a   Moraes, Kátia ^a   Cara, Denise Carmona ^a   Leblanc, Jean Guy ^c   Azevedo, Vasco ^a   Faria, Ana Maria Caetano ^a   Miyoshi, Anderson ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Faculdade de Farmacia   (Brazil)

^c CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

Author keywords

Colitis; Cytokines; Lactococcus lactis; Probiotics; Regulatory T cells

Indexed keywords

EID: 84904772635     PISSN: None     EISSN: 17574749     Source Type: Journal    
DOI: 10.1186/1757-4749-6-33     Document Type: Article

References (54)

1. Genetics and pathogenesis of inflammatory bowel disease. Khor B, Gardet A, Xavier RJ, Nature 2011 474 307 317
2. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. LeBlanc JG, Aubry C, Cortes-Perez NG, de Moreno de LeBlanc A, Vergnolle N, Langella P, Azevedo V, Chatel J-M, Miyoshi A, Bermúdez-Humarán LG, FEMS Microbiol Lett 2013 344 1 1 9
3. Inflammatory bowel disease. Podolsky DK, N Engl J Med 2002 347 417 429
4. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Marteau P, Gut 2006 55 842 847
5. Drug insight: aminosalicylates for the treatment of IBD. Nielsen OH, Munck LK, Nat Clin Pract Gastroenterol Hepatol 2007 4 160 170
6. Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. de Moreno de Leblanc A, Del Carmen S, Zurita-Turk M, Santos Rocha C, van de Guchte M, Azevedo V, Miyoshi A, LeBlanc JG, ISRN Gastroenterol 2011 2011 892971
7. Progress in genomics, metabolism and biotechnology of bifidobacteria. Cronin M, Ventura M, Fitzgerald GF, van Sinderen D, Int J Food Microbiol 2011 149 4 18
8. Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Wescombe PA, Heng NC, Burton JP, Chilcott CN, Tagg JR, Future Microbiol 2009 4 819 835
9. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Kühbacher T, Gut 2006 55 833 841
10. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. Nanda Kumar NS, Balamurugan R, Jayakanthan K, Pulimood A, Pugazhendhi S, Ramakrishna BS, J Gastroenterol Hepatol 2008 23 1834 1839
11. Comparative study of the protective capacity against Salmonella infection between probiotic and nonprobiotic Lactobacilli. Castillo NA, DeMorenode LeBlanc A, de Moreno de LeBlanc AM, Galdeano C, Perdigón G, J Appl Microbiol 2013 114 861 876
12. Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus. Chai W, Burwinkel M, Wang Z, Palissa C, Esch B, Twardziok S, Rieger J, Wrede P, Schmidt MFG, Arch Virol 2013 158 799 807
13. Probiotics in the development and treatment of allergic disease. Isolauri E, Rautava S, Salminen S, Gastroenterol Clin North Am 2012 41 747 762
14. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C, Gastroenterology 2001 121 580 591
15. Inflammatory bowel disease, gut bacteria and probiotic therapy. Reiff C, Kelly D, Int J Med Microbiol 2010 300 25 33
16. MAP kinases contribute to IL-8 secretion by intestinal epithelial cells via a posttranscriptional mechanism. Jijon HB, Panenka WJ, Madsen KL, Parsons HG, Am J Physiol Cell Physiol 2002 283 31 C41
17. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M, J Immunol 2005 174 3237 3246
18. Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. Zhang L, Li N, Caicedo R, Neu J, J Nutr 2005 135 1752 1756
19. Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. Riedel CU, Foata F, Philippe D, Adolfsson O, Eikmanns BJ, Blum S, World J Gastroenterol 2006 12 3729 3735
20. Anti-inflammatory properties of dairy lactobacilli. Santos Rocha C, Lakhdari O, Blottière HM, Blugeon S, Sokol H, Bermudez-Humaran LG, Azevedo V, Miyoshi A, Doré J, Langella P, Maguin E, van de Guchte M, Inflamm Bowel Dis 2012 18 657 666
21. Lactococci as probiotic strains: adhesion to human enterocyte-like Caco-2 cells and tolerance to low pH and bile. Kimoto H, Kurisaki J, Tsuji NM, Ohmomo S, Okamoto T, Lett Appl Microbiol 1999 29 313 316
22. Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. Nishitani Y, Tanoue T, Yamada K, Ishida T, Yoshida M, Azuma T, Mizuno M, Int Immunopharmacol 2009 9 1444 1451
23. Oral tolerance. Faria AM, Weiner HL, Immunol Rev 2005 206 232 259
24. Multiple control of interleukin-8 gene expression. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M, J Leukoc Biol 2002 72 847 855
25. NF-kappaB signaling pathway, inflammation and colorectal cancer. Wang S, Liu Z, Wang L, Zhang X, Cell Mol Immunol 2009 6 327 334
26. Interleukin 8: cells of origin in inflammatory bowel disease. Grimm MC, Elsbury SK, Pavli P, Doe WF, Gut 1996 38 1 90 98
27. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Neurath MF, Pettersson S, Buschenfelde KH M z, Strober W, Nat Med 1996 2 998 1004
28. Live Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Ma D, Forsythe P, Bienenstock J, Infect Immun 2004 72 5308 5314
29. Probiotics inhibit TNF-alpha-induced interleukin-8 secretion of HT29 cells. Bai AP, Ouyang Q, Zhang W, Wang CH, Li SF, World J Gastroenterol 2004 10 455 457
30. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Malin M, Suomalainen H, Saxelin M, Isolauri E, Ann Nutr Metab 1996 40 137 145
31. Screening of intestinal microflora for effective probiotic bacteria. O'Sullivan DJ, J Agric Food Chem 2001 49 1751 1760
32. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R, Gastroenterology 1990 98 694 702
33. Dextran Sodium Sulfate (DSS) Induces Colitis in Mice by Forming Nano-Lipocomplexes with Medium-Chain Length Fatty Acids in the Colon. Laroui H, Ingersoll SA, Liu HC, Baker MT, Ayyadurai S, Charania MA, Laroui F, Yan Y, Sitaraman SV, Merlin D, PLoS One 2012 7 3 32084
34. New Lactococcus strain with immunomodulatory activity: enhancement of Th1-type immune response. Kimoto H, Mizumachi K, Okamoto T, Kurisaki J, Microbiol Immunol 2004 48 75 82
35. Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. Pavan S, Desreumaux P, Mercenier A, Clin Diagn Lab Immunol 2003 10 696 701
36. Mucosal immunity and inflammation. V. Innate mechanisms of mucosal defense and repair: the best offense is a good defense. Podolsky DK, Am J Physiol 1999 277 495 G499
37. IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens. Dann SM, Spehlmann ME, Hammond DC, Iimura M, Hase K, Choi LJ, Hanson E, Eckmann L, J Immunol 2008 180 6816 6826
38. IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis associated cancer. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M, Cancer Cell 2009 16 103 113
39. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, Schirmacher P, Hartmann D, Cichy J, Gavrilova O, Schreiber S, Jostock T, Matthews V, Hasler R, Becker C, Neurath MF, Reiss K, Saftig P, Scheller J, Rose-John S, J Exp Med 2010 207 1617 1624
40. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S, Biochim Biophys Acta 2011 1813 5 878 888
41. Synergy of IL-23 and Th17 cytokines: new light on inflammatory bowel disease. Shen W, Durum SK, Neurochem Res 2010 35 940 946
42. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y, Clin Immunol 2004 110 55 62
43. New insights into the immunological changes in IL-10-deficient mice during the course of spontaneous inflammation in the gut mucosa. Gomes-Santos AC, Moreira TG, Castro-Junior AB, Horta BC, Lemos L, Cruz DN, Guimarães MAF, Cara DC, McCafferty D-M, Faria AMC, Clin Dev Immunol 2012 2012 560817
44. The immunological and genetic basis of inflammatory bowel disease. Bouma G, Strober W, Nat Rev Immunol 2003 3 521 533
45. The fundamental basis of inflammatory bowel disease. Strober W, Fuss I, Mannon P, J Clin Invest 2007 117 514 521
46. Regulatory CD4 + CD25+ cells reverse imbalances in the T cell pool of bone marrow transplanted TGepsilon26 mice leading to the prevention of colitis. Veltkamp C, Gut 2005 54 207 214
47. +T regulatory cells: crosstalk between two professionals in immunity versus tolerance. Chen W, Front Biosci 2006 11 1360 1370
48. Dendritic cells in intestinal immune regulation. Coombes J, Powrie F, Nat Rev Immunol 2008 8 6 435 446
49. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. Jeon SG, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H, Tsuji NM, Kiyono H, Ma JS, Kusu T, Okumura R, Hara H, Yoshida H, Yamamoto M, Nomoto K, Takeda K, PLoS Pathog 2012 8 1002714
50. A xylose-inducible expression system for Lactococcus lactis. Miyoshi A, Jamet E, Commissaire J, Renault P, Langella P, Azevedo V, FEMS Microbiol Lett 2004 239 205 212
51. Two plasmid-determined restriction and modification systems in Streptococcus lactis. Chopin A, Chopin MC, Moillo-Batt A, Langella P, Plasmid 1984 11 260 263
52. Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. Gasson MJ, J Bacteriol 1983 154 1 9
53. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Cooper HS, Murthy SN, Shah RS, Sedergran DJ, Lab Invest 1993 69 238 249
54. Spontaneously developing chronic colitis in IL-10/iNOS double-deficient mice. McCafferty DM, Sihota E, Muscara M, Wallace JL, Sharkey KA, Kubes P, Am J Physiol Gastrointest Liver Physiol 2000 279 90 G99